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Prediction modelsa b s t r a c t
Purpose: Personalized treatments based on predictions for patient outcome require early characterization
of a rectal cancer patient’s sensitivity to treatment. This study has two aims: (1) identify the main pat-
terns of recurrence and response to the treatments (2) evaluate pathologic complete response (pCR)
and two-year disease-free survival (2yDFS) for overall survival (OS) and their potential to be relevant
intermediate endpoints to predict.
Methods: Pooled and treatment subgroup analyses were performed on five large European rectal cancer
trials (2795 patients), who all received long-course radiotherapy with or without concomitant and/or
adjuvant chemotherapy. The ratio of distant metastasis (DM) and local recurrence (LR) rates was used
to identify patient characteristics that increase the risk of recurrences.
Findings: The DM/LR ratio decreased to a plateau in the first 2 years, revealing it to be a critical follow-up
period. According to the patterns of recurrences, three patient groups were identified: 5–15% had pCR and
were disease free after 2 years (excellent prognosis), 65–75% had no pCR but were disease free (good
prognosis) and 15–30% had neither pCR nor 2yDFS (poor prognosis).
Interpretation: Compared with pCR, 2yDFS is a stronger predictor of OS. To adapt treatment most effi-
ciently, accurate prediction models should be developed for pCR to select patients for organ preservation
and for 2yDFS to select patients for more intensified treatment strategies.
 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 114 (2015) 302–309To improve cancer treatment, new hypotheses need to be tested
faster in a suitable cohort of patients to avoid diluting treatment
for insensible patients. Common methods include the use of large
databases [1] and development of reliable surrogate endpoints. A
typical example of such an endpoint is the finding that two-year
disease-free survival (DFS) is correlated with six-year overall sur-
vival (OS) for stage III colon cancer patients treated with adjuvant
chemotherapy [2]. Such surrogate endpoints can be identified early
and have a high prognostic value for survival. By treating them not
as prognostic factors but as intermediate outcomes that can bepredicted by statistical models, future clinical trials could evaluate
individualized treatment strategies, with treatment randomization
differentiated according to these predictions. An example of this
strategy is model based decision making using imaging based
tumor response predictions, which has potential for radiotherapy
boost decisions [3].
Patients with rectal cancer exhibit heterogeneous responses to
treatment; Studies identified a subpopulation of patients whose
tumor is technically unresectable or who refused surgery but were
cured with a low dose of radiotherapy [4]. This subpopulation is
characterized by slow growth and long regression time of rectal
cancer. Patients who achieved a pCR are considered to be a more
favorable subpopulation with less LR and DM as well as better
OS [5,6]. While the prediction of early intermediate endpoints
(e.g., pCR) is less prone to uncertainties and may therefore be more
V. Valentini et al. / Radiotherapy and Oncology 114 (2015) 302–309 303accurate for individualizing treatment, these endpoints may be
weaker prognosticators of long-term outcome.
In this study the value of both DFS and pCR is reported as inter-
mediate endpoints for overall survival in locally advanced rectal
cancer patients. The first aim of this study is to identify the optimal
time point to assess DFS to best separate the population for their
recurrence patterns. A combination of treatment heterogeneity
and a large number of patients in the pooled trial dataset allowed
for sub group analyses of recurrence and response patterns.
Inspired by Gelman et al. [7] patterns of recurrence are analyzed
by calculating the ratio of DM rate and LR rate (which are handled
in general as competing risks) over time to identify a subset of
patients with more versus less aggressive disease.
The second aim of the study was to evaluate pathologic com-
plete response (pCR) and two-year disease-free survival (2yDFS)
as intermediate endpoints in order to build predictive models
which are able to identify patient subgroups before and during
treatment. The rate of pCR may be a suitable endpoint to identify
a subset of patients who could be successfully treated with more
conservative surgery or a non-operative approach. In this setting,
prediction of 2yDFS status may be useful to identify subpopula-
tions with the most aggressive tumors. The two-year timeframe
was chosen based on initial inspection of the data, and may allow
for selection of different chemotherapeutic regimens to reduce DM
rates for this subpopulation using an accurate prediction for 2yDFS
status. If these two intermediate endpoints are able to separate the
rectal cancer population in several risk groups accurate models
predicting these endpoints may allow for better selection of per-
sonalized treatments along the treatment scheme (Fig. S1). It is
beyond the scope of this paper to deliver accurate prediction mod-
els for pCR and 2yDFS, but the focus is on exploration of their role




The analyses were performed on data from five large European
randomized clinical trials for locally advanced rectal cancer
(N = 2795) which were pooled on an individual patient level. This
included the EORTC trial [8] comparing preoperative radiotherapy
with preoperative chemoradiation and observation with postop-
erative chemotherapy in a 2  2 factorial design, the French trial
[9] comparing preoperative radiotherapy with preoperative
chemoradiation, the German trial [10] comparing preoperative
chemoradiation with postoperative chemoradiation, the Polish tri-
al [11] comparing preoperative short-course radiation with
chemoradiation, and the Italian trial [12] comparing observation
with postoperative chemotherapy. The study designs, inclusion cri-
teria, number of patients per trial, and accrual times of the pooled
dataset were described in Valentini et al. [13] All patients in the
pooled dataset received preoperative radiotherapy (RT) with an
average total treatment time of 34–39 days at 1.8 Gy per fraction,
followed by surgery 36–47 days after the end of RT. RT dose and
the possible addition of preoperative and postoperative che-
motherapy (CT) introduced treatment heterogeneity into the data-
base. No patients had metastatic disease at the beginning of
treatment. A total of 24 patients who underwent a local excision
were excluded in advance.
Although many variables were collected in individual clinical
trials, this analysis was restricted to assessing overall survival of
four subpopulations: (1) those who achieved a pCR and were dis-
ease free after 2 years (N = 246, 9.2%), (2) those with pCR but also
a recurrence (N = 21, 0.8%), (3) no pCR but disease free after 2 years(N = 1868, 70.1%) and (4) no pCR and also a recurrence (N = 528,
19.8%). Additional independent variables included RT dose
(<45 Gy, 45 Gy and >45 Gy), administration of concurrent and/or
adjuvant CT (yes/no), the post-RT tumor localization used to deter-
mine the surgery strategy (proximal or distal, depending on the
tumor’s location from the anal verge with 10 cm cut-off), and the
interval between the last fraction of RT and surgery (<28 days,
28–42 days and >42 days).
PCR was defined as the absence of tumor cells in the resected
specimen (ypT0N0). LR was defined as tumor presence in the pelvis
or perineum, or in the anastomosis as confirmed by histology. DM
was defined as evidence of extrapelvic tumor tissue confirmed by
at least two imaging exams. The cumulative incidence of both of
these outcomes was reported separately. The absence of both LR
and DM within 2 years was defined as disease free. Patients with
less than 2 years of follow-up time and without occurrence of an
event (death or recurrence) were excluded from the DFS analysis
(excluded: N = 301).Statistical analysis
Treatment heterogeneity was accounted for by performing sub-
group analyses for the patients receiving different CT regimens in
addition to RT: no CT, concomitant or adjuvant CT, or a combina-
tion of both CTs. The analyses:
1. The risk ratio at time t was defined as the ratio of cumulative
rate of DM at time t divided by the cumulative rate of LR at time
t. By calculating the risk ratio for each year during the follow-up
period, a time trend of the risk ratio was characterized. Confi-
dence intervals were calculated by bootstrapping the ratio of
the two rates from the estimated and normal assumed distribu-
tions to arrive at the ratio distribution.
2. The long-term outcome between the non-pCR and pCR popula-
tions and between non-2yDFS and 2yDFS, as well as five- and
ten-year rates for the cumulative incidence of LR, DM, and OS,
were reported [14] and confidence intervals were based on
the log–log transform [15]. All time intervals were measured
from the date of randomization, except for the analyses pre-
sented in analysis 4 described below.
3. Logistic regression was used to study the impact of characteris-
tics such as sex, age, tumor localization, cT stage, RT dose, and
time to surgery on the odds ratios for the three clinical out-
comes of interest: pCR, 2yDFS, and five-year overall survival
status (5yOS).
4. Overall survival of the subpopulations defined by their pCR and
two-year disease-free status was compared by log rank test,
including the four chemotherapy group stratification. The land-
mark approach [16] was used to avoid the bias of death within
2 years affecting the outcome of investigation (2yDFS).
The analyses were conducted in line with the intention-to-treat
principle, and performed using SPSS (version 15.0) and MATLAB
(version R2010b, MathWorks Inc.).Results
The database characteristics (Table 1) are similar in the four
subgroups, with the exception of roughly 4% more males in the
RT-only subgroup, a higher RT dose in the subgroups with concur-
rent CT and both CTs, more pT0 in the concurrent CT subgroups
compared to the RT-only groups (16.7% and 11.2% vs 5.7% and
3.6%, respectively), and roughly 8% more pN0 for the concurrent
CT subgroup.
Table 1
Clinical and treatment characteristics of the pooled database and the four chemotherapy subgroups: no chemotherapy at all (i.e., only radiotherapy, RT), additional concomitant
chemotherapy only, additional adjuvant chemotherapy only and both of these additional chemotherapies. Characteristics are given in number of patients N and as a percentage of
the total number of those patients in the selected group.
Dataset Pooled RT only RT + conc.chemo RT + adj.chemo RT + both chemo
N [%] N [%] N [%] N [%] N [%]
Patients 2795 [100] 366 [100] 839 [100] 501 [100] 1067 [100]
Sex
Male 1952 [69.8] 268 [73.2] 584 [69.6] 343 [68.5] 740 [69.4]
Female 843 [30.2] 98 [26.8] 255 [30.4] 158 [31.5] 327 [30.6]
Age
Median 62.5 63.0 62.9 62.6 62.0
Range 22.0–81.5 23.0–79.0 28.4–79.0 27.0–78.4 22.0–81.5
cT-stage
1 + 2 18 [0.6] – – 6 [0.7] 1 [0.2] 11 [1.0]
3 2224 [79.6] 309 [84.4] 628 [74.9] 434 [86.6] 841 [78.8]
4 274 [9.8] 41 [11.2] 90 [10.7] 51 [10.2] 92 [8.6]
No data 279 [10.0] 16 [4.4] 115 [13.7] 15 [3.0] 123 [11.5]
cN-stage
0 311 [11.1] 1 [0.3] 230 [27.4] – – 80 [7.5]
+ 551 [19.7] 3 [0.8] 154 [18.3] – – 377 [35.4]
No data 1933 [69.2] 362 [98.9] 455 [54.2] 501 [100] 610 [57.2]
RTdose
<45 Gy 115 [4.1] 18 [4.9] 39 [4.6] 18 [3.6] 40 [3.7]
45–47 Gy 2135 [76.4] 342 [93.4] 645 [76.9] 477 [95.2] 670 [62.8]
>47 Gy 543 [19.4] 6 [1.6] 154 [18.4] 5 [1.0] 357 [33.5]
No data 2 [0.1] – – 1 [0.1] 1 [0.2] – –
Conc.CT
No 867 [31.0] 366 [100] – – 501 [100] – –
Yes 1925 [68.9] – – 839 [100] – – 1067 [100]
No data 3 [0.1] – – – – – – – –
Localization
Proximal 1598 [57.2] 184 [50.3] 491 [58.5] 261 [52.1] 645 [60.4]
Distal 1068 [38.2] 150 [41.0] 319 [38.0] 205 [40.9] 389 [36.5]
No data 129 [4.6] 32 [8.7] 29 [3.5] 35 [7.0] 33 [3.1]
pT-stage
0 299 [10.7] 21 [5.7] 140 [16.7] 18 [3.6] 120 [11.2]
1 191 [6.8] 25 [6.8] 64 [7.6] 37 [7.4] 64 [6.0]
2 816 [29.2] 99 [27.0] 266 [31.7] 133 [26.5] 312 [29.2]
3 1324 [47.4] 185 [50.5] 319 [38.0] 289 [57.7] 520 [48.7]
4 74 [2.6] 15 [4.1] 25 [3.0] 11 [2.2] 22 [2.1]
No data 91 [3.3] 21 [5.7] 25 [3.0] 13 [2.6] 29 [2.7]
pN-stage
0 1879 [67.2] 233 [63.7] 617 [73.5] 309 [61.7] 707 [66.3]
+ 827 [29.6] 116 [31.7] 201 [24] 176 [35.1] 328 [30.7]
No data 89 [3.2] 17 [4.6] 21 [2.5] 16 [3.2] 32 [3.0]
Adj.CT
No 1206 [43.1] 366 [100] 839 [100] – – – –
Yes 1568 [56.1] – – – – 501 [100] 1067 [100]
No data 21 [0.8] – – – – – – – –
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The overall risk ratio between the rates of DM and LR (Fig. 1A)
revealed that, at 1-year follow-up, six times more patients had
developed DM than LR (between 4.2 and 7.5, taking 95% confidence
intervals into account). This number decreases to approximately
2.5 at 2 years and remains relatively constant thereafter, with a
slight negative slope. Fig. 1B shows that approximately 80% of
the recurrences occur within the first 4 years, while deaths occur
later. For the risk ratios of different CT treatment schemes (neoad-
juvant vs adjuvant), similar curves as in Fig. 1 are observed (Fig. 2).
These plots show that adding concomitant CT to RT results in a
higher DM/LR risk ratio over time compared to no concomitant
CT, suggesting that concomitant CT may result in LR reduction
without affecting DM incidence (after 2 years concomitant CT
reduces DM by 14.2% and LR by 49.0% compared to the non-con-
comitant CT population). In addition, the population given CT both
adjuvantly and neoadjuvantly show different behaviors on thosecurves than the other CT schemes, with the ratio staying relatively
constant and decreasing slowly over time. These differences before
and after 2 years are confirmed by the results shown in Fig. S2,
indicating that aggressiveness of disease is increased for early
recurrences, resulting in poor survival, mainly associated with
administration of adjuvant CT. For this reason we consider 2yDFS
a reliable intermediate endpoint to stratify the population.Characterization of populations according to pCR and 2yDFS status
The pCR status was known for 2682 patients; of these, 11.1%
had a pCR (N = 298). There were significant differences in long-
term outcome between the pCR and non-pCR populations (Table 2).
After 10 years, the non-pCR population had a 10.7% higher LR inci-
dence than the pCR population (14.8% vs 4.1%). DM was more fre-
quent in the non-pCR group by 17.1% after 10 years (35.2% vs
18.1%). The pCR population had 73.3% overall survivors vs 57% in
the non-pCR population (16.6% difference). All differences were
V. Valentini et al. / Radiotherapy and Oncology 114 (2015) 302–309 305significant (logrank p-values <.001). In the non-2yDFS population
43.1% had LR and 94.8% had DM at 5 years, and only 12.9% sur-
vived. These numbers are far more favorable for the 2yDFS popula-
tion (6.1%, 16.5%, and 85.3%, respectively).Multivariate analyses
When considering the odds ratio’s for several predictors
(Fig. S3), 2yDFS better resembles OS than pCR as an outcome,
which is significant for sex in the pooled population and for tumor
localization in the adjuvant CT populations. Longer delays between
RT and surgery have an increasing effect on pCR rate but not on
survival rate.Fig. 1. (A) Risk ratio, cumulative rate of distant metastases/cumulative rate of local
recurrences, for all the patients including 95% confidence interval, and (B)
histograms for the percentages of local recurrence and distant metastases occur-
rences (100% = event occurrence at 10 years) for the total population (N = 2795) for
each year of follow-up.pCR vs 2yDFS
Fig. 3 shows that disease-free status at 2 years appears to be a
better predictor of OS than pCR. The landmark analysis shows that
achieving a pCR is significantly beneficial when there is no recur-
rence within 2 years of follow-up. In the case of early recurrence,
pCR status appears to be statistically irrelevant for OS. The greater
effect for OS of achieving 2yDFS than pCR holds for all CT sub-
groups. Due to the low number of patients in the subgroup
pCR + recurrence within 2 years and the similarity in OS curve
development with the no pCR + recurrence group these are consid-
ered as one group in the results. This results in three risk groups:
(1) pCR + 2yDFS in 246 patients (9.3%, with an interval of 2.7–
14.9% depending on treatment group), (2) no PCR + 2yDFS in
1868 patients (70.7% with interval 64.2–76.6%) and (3) no 2yDFS
in 528 patients (20% with interval 17.5–29.3%).
Discussion
This study identified different subpopulations of locally
advanced rectal cancer based on their intermediate outcomes in
a pooled database of five large European randomized trials. We
identified three broad clinical patient subgroups named after their
prognosis:
 Excellent (10% with interval 5–15%): curable patients, highly
treatable, organ preservation to be pursued, identified by a
pCR and 2yDFS.
 Good (70% with interval 65–75%): curable patients, require
effective local treatment, identified by no pCR- and 2yDFS; for
some, the role of combined treatment is questionable.
 Poor (20% with an interval of 17.5–30%): ongoing treatment
strategies do not lead to cure or patients having an early and
late-occurring recurrent disease; They are identified by having
no pCR and no DFS within 2 years.
The overall longer-term aim of the identification of these three
identified groups is to develop accurate prediction models for the
two intermediate outcomes pCR and 2yDFS with data before and
along the treatment. Combined predictions of pCR and 2yDFS (3
risk groups) using clinical, imaging and biomarkers would allow
for personalizing treatment.
Variables related to pathological staging after treatment (pT
stage and pN stage) were found to be the main clinical predictors
of LR, DM, and OS [13], with patients achieving a pCR having an
OS benefit of 14.7% at 5 years and 16.3% at 10 years. This is consis-
tent with previous analyses suggesting better outcomes for
patients with a pCR [5,6]. These studies reported higher five-year
survival rates of 91.6% and 87.6% respectively for patients who
achieve a pCR, compared with 84.3% in the present study. Howev-
er, Maas et al. [6] reported a lower survival benefit of 11.2% at
5 years for patients achieving a pCR. In contrast to our pooleddatabase, both studies used prospective and retrospective results,
and almost all patients received concomitant CT. Therefore, higher
absolute rates for the pCR and non-pCR populations are expected.
Also, the studies in Maas et al. were more recent, and the results
may reflect improved treatment regimens and pathology assess-
ment. Our study shows the long-term benefits of a pCR for the
patients who are recurrence free after 2 years (Fig. 3).
In the current study we did not explore formal analyses of sur-
rogacy, as there were too few trials and the treatments were too
heterogeneous to perform a valid meta-analysis. Previously, the
EORTC 22921 and the FFCD 9203 rectal cancer trials, which are
Fig. 2. Risk ratio, cumulative rate of distant metastases/cumulative rate of local recurrences, for different combinations of given concomitant and adjuvant chemotherapy,
including 95% confidence intervals over 10 years of follow-up.
Table 2
Event rates for pathologic complete response (pCR) vs non-pCR populations and disease free survival at 2 years (2yDFS) vs non-2yDFS at 5 and 10 years of follow-up, including
confidence intervals (CI) and p-values for the log rank test to test if these two populations are significantly different (a = .05).
Outcome Nr. patients 5 years 10 years p-Value HR 95% CI [%]
Rate [%] 95% CI [%] Rate [%] 95% CI [%]
Local recurrence rate
Non-pCR 2415 12.8 [11.5–14.2] 14.8 [12.9–16.9] <.001 0.32 [0.15–0.68]
pCR 267 1.6 [0.6–4.2] 4.1 [1.9–8.7]
Non-2yDFS 611 43.1 [37.6–49.0] 46.0 [39.1–53.5] <.001 10.9 [8.5–14.0]
2yDFS 2184 6.1 [5.0–7.4] 8.3 [6.9–10.0]
Distant metastasis rate
Non-pCR 2415 32.3 [30.4–34.3] 35.2 [33.1–37.4] <.001 0.59 [0.42–0.83]
pCR 267 13.0 [9.3–18.0] 18.1 [12.2–26.5]
Non-2yDFS 611 94.8 [90.8–97.5] 94.8 [90.8–97.5] <.001 21.7 [18.3–25.6]
2yDFS 2184 16.5 [14.8–18.4] 20.5 [18.4–22.8]
Overall survival rate
Non-pCR 2415 69.5 [71.4–67.5] 57.0 [59.5–54.4] <.001 0.73 [0.54–0.98]
pCR 267 84.3 [88.4–78.9] 73.3 [80.5–64.0]
Non-2yDFS 611 12.9 [10.0–16.2] 6.5 [4.1–9.6] <.001 14.1 [12.2–16.4]
2yDFS 2184 85.3 [83.7–86.8] 71.3 [68.5–73.9]
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Fig. 3. Overall survival plots for population stratified for their combined status of pCR and 2yDFS. The time is measured from the chosen landmark of 2 years of follow-up to
avoid bias of already deceased patients before that time. The five plots represent the pooled database and the subgroups based on administered concomitant and/or adjuvant
chemotherapy. Encircled letters A, B, C and D indicate the represented subgroup. Letters with an asterisk indicate which curves are significantly different from the indicated
one with a = .05.
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cy of pCR and progression-free survival (PFS) [17], finding that pCR
was not a qualified surrogate endpoint for PFS and OS, while PFS
was a surrogate endpoint for OS.
For the pCR subgroup with favorable outcomes, lower RT doses
or more conservative surgical strategies might be applied to
improve their quality of life. To individualize these treatmentdecisions, reliable prediction models need to be developed to dis-
tinguish between these pCR subgroups.
In the pCR group, 61% of the LR cases are reported after 5 years
post treatment (5y LR: 1.6%, 10y LR: 4.1%). To our knowledge, this
has not yet been reported in the literature, though it supports
Habr-Gama et al. [18] These findings indicate that patients with
pCR require prolonged observation.
308 Intermediate prediction endpoints for decision making in rectal cancerTwo-year disease-free status was associated with an OS benefit
of 45.5% and 64.8% at 5 and 10 years respectively, compared to
patients with recurrence within 2 years. This supports the identifi-
cation of a population of patients with aggressive disease that
recurs early and leads to poor survival rates, regardless of treat-
ment [8]. While not being the aim of this study, we identified some
prognostic factors, such as sex, cT stage, and tumor localization
(Fig. S3), but more imaging and biological markers should be
explored to predict 2yDFS reliably. Although not tested for in this
paper, pCR status is a plausible prognostic candidate for 2yDFS
based on the studies described above. The comparison between
OS according to pCR and 2yDFS showed that the latter had a stron-
ger predictive impact (Table 2, Fig. 3). A similar result was seen for
patients who received either chemoradiotherapy alone or who
received both chemoradiotherapy and adjuvant CT (Fig. 3).
DFS is superior at predicting survival and should be used as an
intermediate endpoint for new prediction models, with the added
benefit that the outcome is clear at only 2 years follow-up. Accu-
rate prediction of 2yDFS is recommended to select patients for
adjuvant CT regimens.
To decide on more or less aggressive treatments and/or more
QoL-oriented treatments, it is important to identify the subgroup
of patients with early recurrence, because inclusion in prospective
randomized trials may negatively affect the findings. Also, the
recurrence analysis of the DM/LR ratios (Fig. 1) showed a preva-
lence of metastases in the first 2 years, indicating a patient group
with aggressive disease in whom 5-FU based treatment does not
appear to reduce the metastasis rate. The not previously reported
finding that the DM/LR ratio remained flat after 2 years, identifies
a second group of patients with tumors which can become active
after a long follow-up time and have a very slow growth rate. This
may be due to an immunological response, and suggests that
patients should be followed up for an extended period of time. It
appears that for patients receiving concomitant CT the DM/LR ratio
is higher than for the patients without, mainly as a result of the
overall reduction of LR induced by concomitant CT, resulting in
improved local effectiveness without corresponding reduction of
DM (Fig. 2). This effect is seen to a lesser extent for DM.
A limitation of the study is that it is based on older trials, mean-
ing that the quality of imaging, surgery and pathology was not
equal to current standards. Although we believe that the large
number of patients in the pooled dataset provides us sufficient
confidence to support our conclusions, these findings should be
confirmed in newer trials. It should also be emphasized that, in
three trials (N = 1244), adjuvant CT was not randomized or man-
dated; 73% did receive adjuvant CT, and the percentage of these
patients with pN+ stage was significantly higher than in the group
without adjuvant CT, although other factors like age, CRM status
and co-morbidity may be involved as well in the choice for adju-
vant chemotherapy. The higher pN+ frequency may introduce a
possible bias, but it is likely to be small given the patient numbers
involved (14% of the total population had pN+ combined with adju-
vant CT).Conclusion
This study identified different populations of rectal cancer
patients: highly responsive patients (pCR and disease free after
2 years), good responsive curable patients (no pCR but disease free
thereafter), and patients with early and late recurrence regardless
of pCR status (poor prognosis). While both intermediate outcomes
are prognostic (confirming our hypotheses), 2yDFS is stronger than
pCR for OS. pCR predictions may identify a minority of highly
responsive patients for whom surgery can be tailored, organpreservation promoted, and quality of life or other patient-report-
ed outcomes improved, whereas 2yDFS predictions identify less
responsive patients who may benefit from more aggressive CT.
Therefore, 2yDFS should also be considered as an intermediate
endpoint in future trials, focusing on identifying and evaluating
early predictors for pCR and 2yDFS in order to adapt treatment
most efficiently.Conflict of interest statement
None of the authors of paper RO-D-13-00796R1 have conflicts
of interests to publish this paper.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2015.02.
001.
References
[1] Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al.
Delivering affordable cancer care in high-income countries. Lancet Oncol
2011;12:933–80.
[2] Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, et al. Two or three
year disease-free survival (DFS) as a primary end-point in stage III adjuvant
colon cancer trials with fluoropyrimidines with or without oxaliplatin or
irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-
07 and C89803. Eur J Cancer 2011;47:990–6.
[3] Lambrecht M, Deroose C, Roels S, Vandecaveye V, Penninckx F, Sagaert X, et al.
The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging
for response prediction before, during and after preoperative
chemoradiotherapy for rectal cancer. Acta Oncol 2010;49:956–63.
[4] Wang Y, Cummings B, Catton P, Dawson L, Kim J, Ringash J, et al. Primary
radical external beam radiotherapy of rectal adenocarcinoma: long term
outcome of 271 patients. Radiother Oncol 2005;77:126–32.
[5] Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, et al.
Prognostic value of pathologic complete response after neoadjuvant therapy in
locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J
Radiat Oncol Biol Phys 2008;72:99–107.
[6] Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term
outcome in patients with a pathological complete response after
chemoradiation for rectal cancer: a pooled analysis of individual patient
data. Lancet Oncol 2010;11:835–44.
[7] Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved
methodology for analyzing local and distant recurrence. J Clin Oncol
1990;8:548–55.
[8] Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al.
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med
2006;355:1114–23.
[9] Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT,
et al. Preoperative radiotherapy with or without concurrent fluorouracil and
leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol
2006;24:4620–5.
[10] Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al.
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl
J Med 2004;351:1731–40.
[11] Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M,
Kryj M. Long-term results of a randomized trial comparing preoperative short-
course radiotherapy with preoperative conventionally fractionated
chemoradiation for rectal cancer. Br J Surg 2006;93:1215–23.
[12] Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, et al.
No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after
neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum
(LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol
2014 Nov;113:223–9.
[13] Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC,
Bebenek M, et al. Nomograms for predicting local recurrence, distant
metastases, and overall survival for patients with locally advanced rectal
cancer on the basis of European randomized clinical trials. J Clin Oncol
2011;29:3163–72.
[14] Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J
Am Stat Assoc 1958;53:457–81.
[15] Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd
ed. Hoboken (NJ) USA: John Wiley & Sons; 2002.
[16] Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin
Oncol 1983;1:710–9.
V. Valentini et al. / Radiotherapy and Oncology 114 (2015) 302–309 309[17] Bonnetain F, Bosset JF, Gerard JP, Calais G, Conroy T, Mineur L, et al. What is the
clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for
T3–4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials:
surrogacy in question? Eur J Cancer 2012;48:1781–90.[18] Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al.
Patterns of failure and survival for nonoperative treatment of stage c0 distal
rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest
Surg 2006;10(10):1319–28 [discussion 28–9].
